-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Over $4 Million Bet On Werewolf Therapeutics? Check Out These 4 Penny Stocks Insiders Are Buying
Over $4 Million Bet On Werewolf Therapeutics? Check Out These 4 Penny Stocks Insiders Are Buying
The Dow Jones closed higher on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Cryomass Technologies
- The Trade: Cryomass Technologies Inc. (OTC:CRYM) CEO Christian Noel bought a total of 25,000 shares at an average price of $0.16. To acquire these shares, it cost around $3.95 thousand.
- What's Happening: The company's shares have tumbled 30% over the past six months.
- What Cryomass Technologies Does: Cryomass Technologies Inc, formerly Andina Gold Corp provides marketing, IP, and management services to two cannabis dispensaries and to cannabis grow facility, for which cannabis licenses are held by its principal business partner.
biote
- The Trade: biote Corp. (NASDAQ:BTMD) Director Andrew R Heyer acquired a total of 200,000 shares at an average price of $3.00. The insider spent around $600 thousand to buy those shares.
- What's Happening: Biote Announces priced secondary offering of 7.39 million shares of common stock at $3 per share.
- What biote Does: Biote Corp is engaged in bioidentical hormone replacement optimization platform and complementary nutraceutical business.
Check This Out: US Stocks Close Mixed, Market Volatility Increases
Werewolf Therapeutics
- The Trade: Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Rajeev Shah acquired a total of 1,853,000 shares at an average price of $2.21. To acquire these shares, it cost around $4.1 million.
- What's Happening: EF Hutton recently initiated coverage on Werewolf Therapeutics with a Buy rating and announced a price target of $8.3.
- What Werewolf Therapeutics Does: Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.
Don't forget to check out our premarket coverage here
Erasca
- The Trade: Erasca, Inc. (NASDAQ:ERAS) Chairman and CEO Jonathan Lim acquired a total of 60,000 shares at an average price of $3.86. The insider spent $231.42 thousand to buy those shares.
- What's Happening: Erasca, last month, said first patient was dosed in HERKULES-1 Phase 1b trial evaluating ERAS-007 and ERAS-601 MAPKlamp combination in RAS/MAPK pathway-altered solid tumors.
- What Erasca Does: Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
The Dow Jones closed higher on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道琼斯指数周二收高。当内部人士购买或出售股票时,这表明他们对公司前景的信心或担忧。对细价股感兴趣的投资者和交易者可以将其视为影响其整体投资或交易决策的一个因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是近期一些值得注意的细价股内幕交易。欲了解更多,请查看 本辛加的内幕交易 平台。
Cryomass Technologies
Cryomass 科技
- The Trade: Cryomass Technologies Inc. (OTC:CRYM) CEO Christian Noel bought a total of 25,000 shares at an average price of $0.16. To acquire these shares, it cost around $3.95 thousand.
- What's Happening: The company's shares have tumbled 30% over the past six months.
- What Cryomass Technologies Does: Cryomass Technologies Inc, formerly Andina Gold Corp provides marketing, IP, and management services to two cannabis dispensaries and to cannabis grow facility, for which cannabis licenses are held by its principal business partner.
- 交易: Cryomass 科技公司 (场外交易代码:CRYM)首席执行官克里斯蒂安·诺埃尔 共购买了 25,000 股股票 平均价格为0.16美元。收购这些股票的成本约为3.95万美元。
- 发生了什么: 该公司的股价在过去六个月中下跌了30%。
- Cryomass 技术的作用: Cryomass Technologies Inc,前身为Andina Gold Corp,为两家大麻药房和大麻种植设施提供营销、知识产权和管理服务,大麻许可证由其主要商业伙伴持有。
biote
生物群落
- The Trade: biote Corp. (NASDAQ:BTMD) Director Andrew R Heyer acquired a total of 200,000 shares at an average price of $3.00. The insider spent around $600 thousand to buy those shares.
- What's Happening: Biote Announces priced secondary offering of 7.39 million shares of common stock at $3 per share.
- What biote Does: Biote Corp is engaged in bioidentical hormone replacement optimization platform and complementary nutraceutical business.
- 这笔交易: biote Corp (纳斯达克股票代码:BTMD)导演安德鲁·海耶 共收购了20万股股票 平均价格为3.00美元。知情人花了大约60万美元购买了这些股票。
- 发生了什么: Biote宣布将739万股普通股的二次发行定价为每股3美元。
- biote 能做什么: Biote Corp从事生物同源性激素替代优化平台和补充营养品业务。
Check This Out: US Stocks Close Mixed, Market Volatility Increases
看看这个: 美国股市收盘涨跌互现,市场波动加剧
Werewolf Therapeutics
狼人疗法
- The Trade: Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Rajeev Shah acquired a total of 1,853,000 shares at an average price of $2.21. To acquire these shares, it cost around $4.1 million.
- What's Happening: EF Hutton recently initiated coverage on Werewolf Therapeutics with a Buy rating and announced a price target of $8.3.
- What Werewolf Therapeutics Does: Werewolf Therapeutics Inc is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer.
- 这笔交易: Werewolf Therapeutics (纳斯达克股票代码:HOWL)导演拉杰夫·沙阿 共收购了 1,853,000 股股票 平均价格为2.21美元。收购这些股票的成本约为410万美元。
- 发生了什么: EF Hutton最近开始对Werewolf Therapeutics进行报道,评级为买入,并宣布目标股价为8.3美元。
- 狼人疗法是做什么的: Werewolf Therapeutics Inc是一家创新的生物制药公司,率先开发了旨在刺激人体免疫系统治疗癌症的疗法。
Don't forget to check out our premarket coverage here
别忘了在这里查看我们的上市前报道
Erasca
埃拉斯卡
- The Trade: Erasca, Inc. (NASDAQ:ERAS) Chairman and CEO Jonathan Lim acquired a total of 60,000 shares at an average price of $3.86. The insider spent $231.42 thousand to buy those shares.
- What's Happening: Erasca, last month, said first patient was dosed in HERKULES-1 Phase 1b trial evaluating ERAS-007 and ERAS-601 MAPKlamp combination in RAS/MAPK pathway-altered solid tumors.
- What Erasca Does: Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.
- 这笔交易: Erasca, Inc. 纳斯达克股票代码:ERAS)董事长兼首席执行官乔纳森·林 共收购了6万股股票 平均价格为3.86美元。知情人士花了231.42万美元购买了这些股票。
- 发生了什么: 埃拉斯卡上个月表示,在评估 RAS/MAPK 通路改变实体瘤中的 ERAS-007 和 ERAS-601 MapkLamp 组合的 HERKULES-1 1b 期试验中,第一位患者接受了给药。
- 埃拉斯卡在做什么: Erasca Inc是一家临床阶段的精准肿瘤学公司,专门为RAS/MAPK通路驱动型癌症患者发现、开发和商业化疗法。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧